Skip to main content
. Author manuscript; available in PMC: 2017 Nov 1.
Published in final edited form as: Cancer Immunol Res. 2016 Oct 13;4(11):910–916. doi: 10.1158/2326-6066.CIR-16-0201

Table 2.

Outcome (progression-free survival) - Cox univariate and multivariable models

Univariate models HR Std. error P
β2M
β2M decreased/negative 9.2 1.47 0.02

MHC class I
MHC class I decreased/negative 9.7 1.47 0.02

MHC class II
MHC class II decreased/negative 1.2 0.52 0.66

9p24.1 genetic status
9p24.1 amplification 3.3 0.47 0.01

Clinical factors
Advanced stage 3.1 0.46 0.01

Multivariable models HR Std. error P

MHC class I decreased/negative, 9p24.1 amplification
MHC class I decreased/negative 7.3 1.48 0.05
9p24.1 amplification 2.7 0.47 0.03

MHC class I decreased/negative, advanced stage
MHC class I decreased/negative 8.9 1.47 0.03
Advanced stage 2.9 0.47 0.02

MHC class I decreased/negative, advanced stage, 9p24.1 amplification
MHC class I decreased/negative 7.4 1.48 0.05
Advanced stage 2.5 0.47 0.04
9p24.1 amplification 2.3 0.48 0.07